Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.

POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...

Join Fox News for access to this content Plus special access to select articles and other premium content with your account - ...

Alzheimer’s disease (AD) is a neurodegenerative disorder marked by cognitive decline, primarily affecting memory and executive function. This review highlights recent advancements in single-cell ...

Aging is associated with reduced performance in multiple domains of cognition: memory, executive functions (planning, inhibition, manipulating information in one’s mind), language, processing ...

While nearly 7 million Americans aged 65 and older suffer from Alzheimer's disease, experts are reflecting on the advances in diagnosis, treatment and risk management that have been made in 2024.

The frontal lobe is a large part of the brain. It extends from the front of the brain almost halfway to the back, and it helps humans perform complex tasks, innovate, and imagine. This article ...

There's still so much we don't know about Alzheimer's disease, but the link between poor sleep and worsening disease is one that researchers are exploring with gusto. In a study published in 2023, ...

Research on Alzheimer’s disease is approaching a much-needed tipping point. The media spotlight has been on newly available drugs like lecanemab and donanemab that target the protein plaques ...

With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer's disease, the road to a cure seems long and uncertain. But as the year comes to a close, experts are ...

The Professor of Ageing and Intellectual Disability at the School of Nursing and Midwifery, Trinity College Dublin, has been recognised for her transformative work to improve the lives of people with ...

High costs, long wait times and mixed patient outcomes pose a challenge for the U.S. healthcare system. But there’s good news—there’s a new treatment currently undergoing clinical trials ...